Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers Treated With Neoadjuvant Chemotherapy

Targeted Oncology - France
doi 10.1007/s11523-018-0602-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

PB.40. What Happens to the Ductal Carcinoma in Situ in HER2-positive Cancers Treated With Neoadjuvant Chemotherapy and Trastuzumab?

Breast Cancer Research
Cancer ResearchOncology
2014English

Prognostic and Predictive Values of EGFR Overexpression and EGFR Copy Number Alteration in HER2-positive Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2014English

Clinical Significance and Prognostic Value of Receptor Conversion in Hormone Receptor Positive Breast Cancers After Neoadjuvant Chemotherapy

World Journal of Surgical Oncology
SurgeryOncology
2018English

Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting

Oncologist
Cancer ResearchMedicineOncology
2016English

Prognostic Value of HER2 to CEP17 Ratio on Fluorescence in Situ Hybridization Ratio in Patients With Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated With Neoadjuvant Chemotherapy With or Without Trastuzumab

Oncologist
Cancer ResearchMedicineOncology
2020English

Evaluation of Prognostic Factors and Validation of Tumor Response Ratios After Neoadjuvant Chemotherapy in Patients With Breast Cancer

Journal of Breast Disease
2016English

Erratum To: Effect of Neoadjuvant Chemotherapy on Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Breast Cancer and Its Clinical Significance

Breast Cancer Research
Cancer ResearchOncology
2017English

Prognostic and Predictive Role of Tumour-Associated Macrophages in HER2 Positive Breast Cancer

Scientific Reports
Multidisciplinary
2019English

Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy